Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cadrenal Therapeutics(CVKD) the EBIT is -3.34 M (+10.55%), Beat estimate;the EPS is -1.14 (+39.04%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B10.55%
-0.00B3.60%
+0.00B6.95%
EPSExceed expectations
-1.1439.04%
-1.15538.24%
+0.01500.80%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf